Innovations in healthcare has shown astounding growth in the past decade from 3D printing of arteries and prosthetics to treatments in diabetes. Though the goal is to do more than just assuage the constant struggle of diabetes sufferers, medical care is heading in the right direction with these 5 new innovations:
Finger Sticks Reduction
One of the complaints heard often from those with diabetes is the pain of finger sticks, and though continuous glucose monitors (CGMs) make it easier to see data, the calibrations have presented problems which can cause a need for more finger sticks.
Abbott’s FreeStyle Flash Glucose Monitoring System intends to answer this concern with its new system that doesn’t need calibration or blood glucose meter. It only uses finger-stick tests for confirmation readings below 70 mg/dl. A small sensor with under the skin filament is held under the arm with adhesive giving a reading of glucose levels minute-by-minute and can read through clothing. The device can store 3 months of data which is useful to track trends.
It has launched in some EU countries and is working on coming Stateside in the near future.
Pump It Up
The modern designed Medtronic’s 640G cuts down on the bulk with its hybrid design. It acts as both a hybrid pump and CGM. The device acts as a pump but monitors the levels to prevent unhealthy limits of insulin. The device is available in Australia and is expected to launch in the U.S. shortly.
Something as simple as forgetting to take your insulin can lead to not-so-simple problems. Under or over-taking your insulin can be a problem that Timesulin is aiming to wipe out. Timesulin has a timer that starts counting the minute you cap your pen so you’ll be able to see when you took your last dose at a glance on its digital meter. This device works with most pen brands and is already in the U.S.
Sanofi and MannKind Corp are in works to offer an alternative to rapid-acting insulin in the form of Afrezza, an insulin powder you use like an asthma inhaler before a meal. The insulin works faster than injected rapid-acting insulin, clears from the body more readily, and cuts down the risk of hypoglycemia. This drug is not intended for smokers, those with asthma, or other lung-related illnesses. Afrezza is already available in the United States for both Type 1 and 2 diabetes.
In its search to provide a less intrusive method for diabetes to take their medication, Intarcia is looking below skin level. The matchstick-sized device would be implanted below the skin to deliver a constant dose of exenatide for type 2 diabetes which is generally injected twice a day. This device would only need to be injected twice a year significantly cutting down the discomfort of injections. This device plans to clear FDA sometime next year.
These are only 5 of the innovations available or heading our way. There are many more listed at the Diabetes Forecast site. With the trajectory of innovations moving towards alleviating at least some of the problems, the hope is that this momentum will continue and offer even more solutions moving forward.